Why balance is important amid equity market volatility

Equity markets have performed well this year, but returns have been concentrated in a narrow subset of the market, namely artificial intelligence (AI) and artificial incretins (GLP‑1s). However, we are entering a key earnings season in which many of the significant outperformers year‑to‑date may begin to see a slowing rate of returns improvement. In our experience, fundamental momentum tends to matter more in the short term for relative performance and valuation, and therefore the margin for error is smaller.

Corporate earnings for many large technology and health care companies have been strong over the past 18 months. However, in terms of the AI infrastructure buildout, we believe we are clearly past the early phase of adoption and most meaningful inflection in spending. It is wise at this point to question whether the current pace of capital expenditure growth can be sustained at these levels. The risk of an unexpected surprise in terms of earnings guidance could prompt a rotation out of AI names. That needs to be managed in a strategic manner, especially from a factor risk perspective.

We have for some time treated our exposure to the so‑called Magnificent Seven (Apple, Microsoft, Alphabet, Amazon, NVIDIA, Meta Platforms, and Tesla) as a separately defined sector. That allows more potential to govern the impact on portfolio returns versus the benchmark, particularly given the unusually high concentration of these stocks in market indices. The bar is now set extremely high for these companies in terms of earnings delivery—a risk that warrants due consideration.¹

While the initial infrastructure cycle for AI may be peaking, we are, however, only just beginning to see the potential benefits of AI in other areas. In the next few years, we expect to see an acceleration in terms of speed, productivity, and innovation as companies employ their AI capabilities. The potential is not limited to technology—it traverses nearly every sector and industry, some that may not be immediately obvious. Energy, industrials, and even real estate are all potential beneficiaries of the AI cycle.

The other seismic shift of recent years has been health care innovation, specifically the development of GLP‑1s. We feel much more optimistic about the potential of this area in the near term. The benefits of these drugs keep expanding (see graphic). GLP‑1s have been lauded, including claims that obesity could potentially be cured in the next 10 years. This has significant repercussions. The ability of the drugs to regulate body weight at a relatively low cost has huge potential benefits for both society and economies.

An oral version of GLP‑1s is being developed and is likely to be available sooner rather than later. This would potentially see much greater adoption, and with it improved earnings for their manufacturers. Growth forecasts, however, will depend on constraints around capacity and the ability to deliver as demand increases.

Rising valuations and a stretched investment cycle demand consideration of the potential for market rotation. Building a portfolio that invests in technology and health care is important given the seismic shifts underway. But exposure here must be balanced with other areas such as energy, financials, industrials, and even consumer staples. These sectors have historically offered defensive qualities and steady growth that could potentially provide a buffer against market volatility.

The wider macroeconomic backdrop is also a key consideration. As we have conveyed previously, we believe we are in the early stages of an equilibrium shift. One where the economy has veered from abundance to scarcity. This will likely see inflation remain stickier and interest rates higher for longer. Geopolitical risks play into this dynamic. A more dangerous world means a higher risk premium put on natural resources and a greater importance on supply chain independence. The U.S. presidential election cycle adds another level of complexity with different policy implications.

This mosaic of changes means that the playing field for investing is changing. Yet, this is where active management can take control. If the game has changed, it’s important to change your strategy. But we believe this new equilibrium path offers new and broader opportunities, alongside a potential to build a better risk profile.

The specific securities identified and described are for informational purposes only and do not represent recommendations. No assumptions should be made that investments in the securities identified and discussed were or will be profitable.

Risks: International investments can be riskier than U.S. investments due to the adverse effects of currency exchange rates, differences in market structure and liquidity, as well as specific country, regional, and economic developments. Investing in technology stocks entails specific risks, including the potential for wide variations in performance and usually wide price swings, up and down. Health sciences firms are often dependent on government funding and regulation and are vulnerable to product liability lawsuits and competition from low‑cost generic product. Because of the cyclical nature of natural resource companies, their stock prices and rates of earnings growth may follow an irregular path. Real estate is affected by general economic conditions. When growth is slowing, demand for property decreases and prices may decline. Financial services companies may be hurt when interest rates rise sharply and may be vulnerable to rapidly rising inflation.

Call 1-800-225-5132 to request a prospectus or summary prospectus; each includes investment objectives, risks, fees, expenses, and other information you should read and consider carefully before investing.